DF/HCC Program Affiliation

Outcomes Research
Gastrointestinal Malignancies

DF/HCC Associations

BIDMC, GI, Clinical Trial Chairs

Research Abstract

Dr. Miksad is engaged in health services and outcomes research as an attending GI oncologist at Beth Israel Deaconess Medical Center and as a Senior Scientist at the Institute for Technology Assessment at Massachusetts General Hospital. Her research has been supported by a Young InvestigatorAward from the American Society of Clinical Oncology. Her current and past research support includes the PCORT fellowship, the Young Investigator’s Award from the American Society of Clinical Oncology, the Timely Special Opportunity Award from the Dana-Farber Cancer Institute, the NIH Loan Repayment Program and the Clinical Research Feasibility Fund Award from BIDMC. Recent awards include the Lee Lusted Prize for outstanding research from the Society for Medical Decision Making and the Clinical Research Award from the Eastern Cooperative Oncology Group.

Rebecca received a B.A in economics from Harvard, an MD with honors in research from Cornell University, and an MPH from Harvard. She completed her internal medicine residency at New York-Presbyterian Hospital and her Hematology/Oncology fellowship at BIDMC. She completed the NCI-funded post-doctoral fellowship in the Dana-Farber/Harvard Cancer Center Program in Cancer Outcomes Research Training (PCORT). Rebecca’s research goals are to improve oncology treatment decision making through better characterization of cancer patient outcomes, improved accuracy of clinical endpoints, assessment of the economic implications of cancer therapy and application of decision analysis tools. Dr. Miksad current and recent research projects include:

1) Efficacy neoadjuvant sorafenib for radiofrequency ablation of localized hepatocellular carcinoma (HCC)
2) Hepatobiliary cancer clinical trials and liver cancer outcomes
3) Surrogate endpoint evaluation and validation in cancer trials
4) Bayesian analysis / novel oncology clinical trial evaluation
5) Decision analysis and cancer modeling
6) Quality of life of cancer patients

Publications

• Swan JS, Miksad RA.Measuring the quality-of-life effects of diagnostic and screening tests.J Am Coll Radiol 2009 Aug;6(8):567-75.
  19643385
• Zhu AX,Sahani DV,Duda DG,di Tomaso E,Ancukiewicz M,Catalano OA,Sindhwani V,Blaszkowsky LS,Yoon SS,Lahdenranta J,Bhargava P,Meyerhardt J,Clark JW,Kwak EL,Hezel AF,Miksad R,Abrams TA,Enzinger PC,Fuchs CS,Ryan DP,Jain RK.Efficacy, Safety, and Potential Bioma
  19470923
• Miksad RA,Gonen M,Lynch TJ,Roberts TG Jr.Interpreting trial results in light of conflicting evidence: a Bayesian analysis of adjuvant chemotherapy for non-small-cell lung cancer.J Clin Oncol 2009 May 1;27(13):2245-52.
  19307513
• Miksad RA,Zietemann V,Gothe R,Schwarzer R,Conrads-Frank A,Schnell-Inderst P,Stollenwerk B,Siebert U.Progression-free survival as a surrogate endpoint in advanced breast cancer.Int J Technol Assess Health Care 2008 Fall;24(4):371-83.
  18828930
• Muhlberger N, Sroczynski G, Esteban E, Mittendorf T, Miksad RA, Siebert U.Cost-effectiveness of primarily human papillomavirus-based cervical cancer screening in settings with currently established Pap screening: A systematic review commissioned by the Ge
  18400122
• Miksad RA, Schnipper L, Goldstein M.Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value?.J Clin Oncol 2007 Oct 1;25(28):4506-7; author reply 4508.
  17906218
• Levy NC, Miksad RA, Fein OT.From treatment to prevention: the interplay between HIV/AIDS treatment availability and HIV/AIDS prevention programming in Khayelitsha, South Africa.J Urban Health 2005 Sep;82(3):498-509.
  16049203